Background: Simultaneous pancreas-kidney transplant (SPKT) outcomes have improved over the years. Methods: Analyses of demographic data of patients submitted to SPKT from Dec/2000 to Sep/2015 and the impact of virtual crossmatch (A, B, C, DP, DQ, and DR) on reduction of cold ischemia time (CIT). Kaplan-Meier curve and t-test were used for statistical analyses. Results: 441 patients were submitted to SPKT at Federal University of São Paulo: no induction (n=232), Thymoglobuline (n=153), and Basiliximab (n=56). Recipient: 35.5±7.7-year-old, 58.9% male, 75.8% Caucasian, dialysis duration 39.2±22.8 months, and diabetes history 21.9±6.1 years. Donor: 26.6±9.4-year-old and 63% non-cardiovascular cause of death. Patient, kidney, and pancreas 15-yr survival rates were 78.6%, 72.5%, and 66.7%, respectively. Patient, kidney and pancreas 15-yr survival rates using induction therapy with Thymoglobuline or Basiliximab were 86.2% and 85.1% versus 72.9% in the group without induction (P=0.02); 79.2% and 81.2% versus 65.6% in the group without induction (P=0.017); and 70.2% and 77.2% versus 60.2% in the group without induction (P=0.037), respectively. In Aug/2013, virtual crossmatch was set up at our institution and contributed to decrease both kidney (15.1± 0.3h versus 11.9±0.5h, P=0.0004) and pancreas (15.1±0.2h versus 11.3±0.4h, P<0.0001) CITs and delayed kidney graft function rates (23.8% versus 11%, P=0.016). One-year acute rejection rates did not increase after virtual crossmatch set-up. Conclusions: Virtual crossmatch is safe in SPKT and may contribute to increase patient and grafts survival rates when combined to induction therapy.

CITATION INFORMATION: Bevilaqua Rangel E, Miziara Gonzalez A, Santiago Melaragno C, de Sa J, Moura Linhares M, Salzedas-Neto A, de Marco R, de Lima M, Medina-Pestana J. Virtual Crossmatch in Simultaneous Pancreas-Kidney Transplant. Am J Transplant. 2016;16 (suppl 3).

« Back to 2016 American Transplant Congress